Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01238107
Other study ID # MT-102-2001
Secondary ID
Status Completed
Phase Phase 2
First received November 9, 2010
Last updated September 9, 2014
Start date April 2011
Est. completion date May 2013

Study information

Verified date September 2014
Source PsiOxus Therapeutics Ltd
Contact n/a
Is FDA regulated No
Health authority United Kingdom:Medicines and Healthcare Regulatory AgencyBelguim:Federal Agency for Medicines and Healthcare ProductsIndia:Directorate General of Health ServicesMalaysia:Ministry of Health Malaysia
Study type Interventional

Clinical Trial Summary

A phase II clinical study to evaluate MT-102 administered over a sixteen week period in subjects with cachexia related to non-small cell lung cancer and colorectal cancer


Description:

Cachexia is a wasting disease, associated with significant morbidity and mortality, accompanying a wide range of serious illnesses, for which there are currently no widely approved therapeutic agents. Cachexia is defined as weight loss, associated with a chronic underlying disease, of at least 5% in 12 months or less. It is associated with fatigue, loss of muscle strength, a low fat free index and neurohormonal and biochemical abnormalities.

Cancer cachexia occurs in about a third of all patients with cancer and has been estimated to be the direct cause of death in up to 20% of all cancer related deaths. As with other solid tumours, colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) have relatively high incidences of cachexia, approximately 28% and 34% respectively.Through its combined pharmacological actions, MT-102 has a multi-functional effect upon three potential pharmacological targets, each of which is relevant for cancer cachexia


Recruitment information / eligibility

Status Completed
Enrollment 87
Est. completion date May 2013
Est. primary completion date May 2013
Accepts healthy volunteers No
Gender Both
Age group 25 Years to 80 Years
Eligibility Inclusion Criteria:

- 1. Adult patients aged between 25 to 80 years of age and with a life expectancy of greater than 3 months as judged by the treating physician.

2. Confirmed diagnosis of one of:

a. Non-curative stage III or stage IV Colorectal Cancer (CRC) not suitable for surgery, or b. Non-curative stage III or stage IV Non-small Cell Lung Cancer (NSCLC) not suitable for surgery;

3. Patients who are receiving or who have already received a course of chemotherapy, with or without radiotherapy or surgery, with one of the following regimes:

a. For non-small cell lung cancer, a platinum based regimen b. For colorectal cancer, a 5FU or Irinotecan based regimen

4. Cachexia with ongoing weight loss that in the opinion of the investigator is due to the underlying cancer.

5. Evidence of cachexia as judged by one of:

a. =5% documented weight loss in the previous 12 months; or b. A subjective report of weight loss in the previous 12 months and a recorded body mass index (BMI) less than 20.0 kg/m2 c. Ongoing documented weight loss of at least 1kg in the week prior to day 0; or 1.25kg in the 2 weeks prior to day 0, or 1.5kg in the 3 to 6 weeks prior to day 0; provided that BMI is not more than 25.

6. At least two of the following:

a. Subjective report of decreased muscle strength b. Subjective report of fatigue c. Subjective report of anorexia d. Abnormal biochemistry with one or more of the following: i. CRP > ULN (as per Central Lab normal value) ii. Anemia (< 12 g/dl) iii. Low serum albumin (< 3.2 g/dl) 7. Patients of childbearing potential must use an effective method of avoiding pregnancy (including oral, transdermal, or implanted contraceptives; an intrauterine device; male or female condoms; diaphragm or cervical cap with spermicide; or abstinence) prior to randomisation and must agree to continue using such precautions until the end of the 140 day safety follow up; 8. Willing and able to comply with the protocol and to complete the study period; 9. Willing to forego other forms of experimental treatment during the study; 10. Signed and dated informed consent, prior to receipt of any study medication or any study related procedures.

11. ECOG performance status 0, 1 or 2 12. Able to complete the performance tests (SCP, SMWT, SPPB, HGS) at the screening visit and with two consecutive pre-randomisation SMWT results that differ by no more than 30% from each other 13. At least 80% compliant during the placebo run in period

Exclusion Criteria:

1. 1. Pregnancy or lactation at screen or baseline visit;

2. =20% weight loss in the previous 3 months or a BMI of less than 16 kg/m2

3. Age greater than 80 or less than 25 at baseline visit;

4. Scheduled to start any new course of chemotherapy or to undergo a change in present chemotherapeutic regimen during the dose escalation phase of the study (the first three weeks after randomisation);

5. Any surgical procedure within the past month or any planned surgical procedure;

6. Any mechanical obstruction of the alimentary canal;

7. Any history or evidence of intractable vomiting;

8. A history or clinical evidence of any hyperthyroidism, cirrhosis, hepatic failure, HIV, renal failure (as determined by a serum creatinine > 250µmol/l or > 2.83 mg/dl at screen) or active tuberculosis (as confirmed by sputum or other microbiological methods, within the last five years);

9. Any physical, medical, socioeconomic or other non-cancer related cause for simple starvation, muscle wasting or weight loss;

10. Receiving enteral tube feeding or parenteral nutrition at screening or baseline visit;

11. Any clinical evidence of ascites or significant oedema or significant pleural effusion at screening or baseline visit;

12. Current or planned treatment with

1. Any oral adrenal corticosteroids (inhaled or topical steroids and short-term use of dexamethasone around the time of chemotherapy are acceptable);

2. Beta adrenergic blockers,

3. Non-dihydropyridine calcium antagonists (e.g. Verapamil, diltiazem),

4. Alpha adrenergic blockers,

5. Ivabradine (Coralan, Procoralan),

6. 5HT agonists or antagonists e.g. SSRI's, , (short-term use around the time of chemotherapy are acceptable)

7. MAOI's,

8. Beta agonists, (short term or on-and -off use of inhaled broncho-dilators are acceptable)

9. Amiodarone,

10. Megestrol, Anabolic Steroids or any other prescription medication intended to increase appetite or to treat unintentional weight loss.

13. Treatment with any investigational drug therapy within 28 days prior to the screening visit;

14. Previous history of administration of pindolol or s-pindolol;

15. History of allergy or reaction to any component of the MT 102/study drug formulation;

16. History or presence of congestive heart failure (with LVEF <45%) or uncontrolled hypertension (with BP >160/95 mm Hg);

17. Use of a pacemaker, implantable defibrillator, or internalized metal stent;

18. Resting pulse rate less than 68 beats per minute or high degree conduction defect on the electrocardiogram;

19. A resting supine systolic blood pressure less than 100 mm Hg.

20. A history of bronchospasm and bronchial asthma;

21. History or diagnosis of brain metastases

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
MT-102
BETA BLOCKER

Locations

Country Name City State
Germany Charite Hospital Virchow-Klinikum Campus Berlin
India Vedanta Institute of Medical Science Ahmedabad Gujarat
India Shree Krishna Hopsital Anand Gujarat
India Kailash Cancer Hospital & Research Centre Goraj Gujarat
India Kumaran Hospital Private Ltd Kilpauk Chennai
India TATA Memorial Hopsital Mumbai Maharashtra
India Curie Manavta Cancer Centre Nashik Maharashtra
India Shatabdi Super Speciality Hospital Nashik Maharashtra
India Dr Kamakshi Memorial Hospital Pallikaranai Chennai
India Noble Hopsital Pune
Malaysia Hospital Sultahan Bahiyah Alor Setar Kedha
Malaysia Hospital Universiti Kebangsaan Malaysia Cheras Kuala Lumpur
Malaysia Universiti Malaya Medical Jalan Baharu Kuala Lumpur
Malaysia International Islamic University Malaysia Kuantan Pahang
Malaysia Hospital Universiti Sains Malaysia Kubang Kerian Kelantan
Malaysia Hospital Umum Sarawak Kuching Sarawak
Malaysia Penang General Hopsital Pulau Pinang Penang
Malaysia Tuanku Ja'afar Hospital Seremban Negeri Sembilan

Sponsors (2)

Lead Sponsor Collaborator
PsiOxus Therapeutics Ltd Veeda Oncology

Countries where clinical trial is conducted

Germany,  India,  Malaysia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Demonstrate the effect of a 10mg / bd dose of MT-102 in comparison to placebo on the rate of weight change over a sixteen week period in patients with cachexia related to underlying stage III and stage IV colorectal or non-small cell lung cancer 16 weeks No
See also
  Status Clinical Trial Phase
Recruiting NCT02553187 - A Prospective, Randomized, Controlled, Multicenter Study of Kanglaite Injection for the Treatment of Cancer Cachexia Phase 4
Recruiting NCT02848807 - Chemotherapy-related Toxicity, Nutritional Status and Quality of Life N/A
Active, not recruiting NCT01206335 - Open Label Study With OHR/AVR118 in Advanced Cancer Patients With Anorexia-Cachexia Phase 2
Completed NCT00378131 - Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia Phase 2
Completed NCT02359123 - Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients N/A
Completed NCT00267358 - Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia. Phase 2
Completed NCT03144128 - Vitamin D for Muscle Metabolic Function in Cancer Cachexia N/A
Completed NCT01614990 - Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia Phase 2
Recruiting NCT04067167 - Flexi Band Resistance Training Versus EMS Exercise in Patients With the Diagnosis of Malignant Diseases N/A
Recruiting NCT04065815 - Protein-rich Nutritional Therapy Combined With Time-efficient Exercise in Cancer Therapy N/A
Active, not recruiting NCT03851133 - Florida Pancreas Collaborative Next Generation Biobank
Completed NCT05264038 - A First in Human Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics Effects of OC514 Phase 1
Recruiting NCT04127981 - Medical Imaging of Cachexia N/A
Not yet recruiting NCT05262192 - Nutrition Education and Quality of Life in Cancer Cachexia N/A
Completed NCT04153019 - PSYCHO-EDUCATIONAL AND REHABILITATIVE INTERVENTION FOR CANCER CACHEXIA (PRICC) N/A
Terminated NCT02066363 - Study of Parenteral Nutrition to Patients With Gastrointestinal Cancer N/A
Terminated NCT01505764 - The Role of Ghrelin in Cancer Cachexia Phase 2
Completed NCT00219817 - Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss Phase 2
Completed NCT00094562 - A Fish Oil Supplement to Maintain Body Weight in Patients With Disease-Related Weight Loss Phase 2
Recruiting NCT04131478 - Effect of Gene Polymorphisms on the Pathogenesis of Cancer Cachexia